Condition: ALK+ Non-Small-Cell Lung Carcinoma · Sponsor: Pfizer
Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World context
This description comes directly from the study's public registry record.
Pfizer CT.gov Call Center · 1-800-718-1021 · ClinicalTrials.gov_Inquiries@pfizer.com
Always discuss trial participation with your own doctor first.
| Institut Curie | Paris, Paris, France | Recruiting |
| Centre Hospitalier du Pays d AIX | Aix-en-Provence, France | Recruiting |
| CH ALBI | Albi, France | Recruiting |
| Chu Amiens Sud | Amiens, France | Recruiting |
| Ch Avignon | Avignon, France | Not Yet Recruiting |
| Polyclinique Bordeaux Nord Aquitaine | Bordeaux, France | Not Yet Recruiting |
| Institut Bergonie | Bordeaux, France | Not Yet Recruiting |
| Hopital Morvan | Brest, France | Not Yet Recruiting |
| CHIC | Créteil, France | Recruiting |
| Clcc Georges Francois Leclerc | Dijon, France | Recruiting |
| Hopital de Villefranche Sur Saone | Gleizé, France | Not Yet Recruiting |
| Chu Limoges | Limoges, France | Recruiting |
+ 19 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06487078